Home › Calculator › MEOBF Dividend Calculator 2026
MEOBF Dividend DRIP Calculator 2026
105.26% YieldHealthcareMesoblast Limited · OTC
Price: $1.90 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When MEOBF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your MEOBF snowball 📈
$10,000 in MEOBF → $25.38M in 10 years · $2,172.33/month
About Mesoblast Limited (MEOBF) — Dividend Analysis 2026
Mesoblast Limited, an Australian biopharmaceutical company established in Melbourne in 2004, specializes in the development and global commercialization of allogeneic cellular medicines. With operations spanning the United States, Australia, Singapore, the United Kingdom, and Switzerland, the firm leverages a proprietary regenerative medicine platform based on specialized mesenchymal lineage cells. This technology underpins treatments for a wide spectrum of conditions, including cardiovascular, spinal orthopedic, oncological, hematological, immune-mediated, and inflammatory diseases. The company's advanced pipeline includes several products in Phase III clinical trials. Remestemcel-L is being investigated for steroid-refractory acute graft versus host disease (GvHD) and acute respiratory distress syndrome (ARDS) linked to COVID-19 infection. Rexlemestrocel-L is progressing for advanced chronic heart failure, while MPC-06-ID targets chronic low back pain resulting from degenerative disc disease. Additionally, Mesoblast is developing MPC-300-IV for biologic-refractory rheumatoid arthritis and diabetic nephropathy. Strategic partnerships are integral to Mesoblast's operations. The company collaborates with Tasly Pharmaceutical Group to market MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China. A partnership with JCR Pharmaceuticals Co. Ltd. focuses on wound healing for patients with epidermolysis bullosa. Furthermore, Mesoblast works with Grünenthal to develop and commercialize cell therapy for chronic low back pain.
Compare MEOBF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full MEOBF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open MEOBF position with:
🌍 MEOBF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold MEOBF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 105.26% | 102.46% | $10,526 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 89.47% | 86.67% | $8,947 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 84.21% | 81.41% | $8,421 / yr |
| 🇬🇧 UK ISA | 0% | 105.26% | 102.46% | $10,526 / yr |
| 🇬🇧 UK Taxable | 8.75% | 96.05% | 93.25% | $9,605 / yr |
| 🇨🇦 TFSA | 0% | 105.26% | 102.46% | $10,526 / yr |
| 🇨🇦 CA Taxable | 25% | 78.95% | 76.15% | $7,895 / yr |
| 🇦🇺 Super (pension) | 15% | 89.47% | 86.67% | $8,947 / yr |
| 🇦🇺 AU Taxable | 30% | 73.68% | 70.88% | $7,368 / yr |
| 🇩🇪 DE Taxable | 26.375% | 77.50% | 74.70% | $7,750 / yr |
| 🇫🇷 FR Taxable | 30% | 73.68% | 70.88% | $7,368 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 MEOBF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 MEOBF Dividend Payment Schedule
MEOBF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 MEOBF vs Healthcare Benchmarks
How MEOBF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for MEOBF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ MEOBF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where MEOBF earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the MEOBF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Mesoblast Limited (MEOBF) is currently trading at $1.90, 29% below its 52-week high. The current dividend yield is 105.26% based on an annual payout of $2.00 per share.
MEOBF (Mesoblast Limited) — 105.26% Dividend Yield Analysis
Mesoblast Limited (MEOBF) is a healthcare stock currently trading at $1.90 with a dividend yield of 105.26%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (105.26%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.